“Behind-The-Counter” Drug Switches Must Tackle Restrictions On Use For Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.